PharmaShots | Incisive News in 3 Shots

Subscribe Now

First Patient Dosing

Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis

Dermavant Reports the First Patient Dosing in P-III ADORING Program of Tapinarof for the Treatment of Atopic Dermatitis

September 10, 2021

$Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma$

Caribou Reports the First Patient Dosing in P-I ANTLER Study of CB-010 to Treat Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

July 14, 2021

Henlius Reports First Patient Dosing in P-II/III Study of HLX10 + HLX04 (biosimilar- bevacizumab) for 1L mCRC

Henlius Reports First Patient Dosing in P-II/III Study of HLX10 + HLX04 (biosimilar- bevacizumab) for 1L mCRC

March 11, 2021

Henlius Reports First Patients Dosing in P-I Study of HLX14 (denosumab- biosimilar)

Henlius Reports First Patients Dosing in P-I Study of HLX14 (denosumab- biosimilar)

November 11, 2020

Henlius Reports First Patient Dosing with HLX11 (biosimilar- pertuzumab) for HER2-Positive Metastatic Breast Cancer and Early Breast Cancer

Henlius Reports First Patient Dosing with HLX11 (biosimilar- pertuzumab) for HER2-Positive Metastatic Breast Cancer and Early Brea...

September 20, 2020

Bicycle Reports First Patient Dosing in P-IIa Study of BT1718 for MT1-MMP-Positive Squamous NSCLC

Bicycle Reports First Patient Dosing in P-IIa Study of BT1718 for MT1-MMP-Positive Squamous NSCLC

September 3, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us